Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality

OBJECTIVE: Experimental evidence has shown potential cardioprotective actions of phosphodiesterase type-5 inhibitors (PDE5is). We investigated whether PDE5i use in patients with type 2 diabetes, with high-attendant cardiovascular risk, was associated with altered mortality in a retrospective cohort...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Heart
Päätekijät: Anderson, Simon G, Hutchings, David C, Woodward, Mark, Rahimi, Kazem, Rutter, Martin K, Kirby, Mike, Hackett, Geoff, Trafford, Andrew W, Heald, Adrian H
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2016
Aiheet:
Cardiac Risk Factors and Prevention
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5099221/
https://ncbi.nlm.nih.gov/pubmed/27465053
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/heartjnl-2015-309223
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia